MedCap AB (publ)
STO:MCAP

Watchlist Manager
MedCap AB (publ) Logo
MedCap AB (publ)
STO:MCAP
Watchlist
Price: 558 SEK -1.85% Market Closed
Market Cap: kr8.4B

Wall St Price Targets

MCAP Price Targets Summary
MedCap AB (publ)

Wall Street analysts forecast MCAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MCAP is 652.8 SEK with a low forecast of 626.2 SEK and a high forecast of 693 SEK.

Lowest Forecast
Price Target
626.2 SEK
12% Upside
Average Forecast
Price Target
652.8 SEK
17% Upside
Highest Forecast
Price Target
693 SEK
24% Upside
MedCap AB (publ) Competitors:
Price Targets
MRKR
Marker Therapeutics Inc
547% Upside
DHR
Danaher Corp
11% Upside
VSEC
VSE Corp
35% Upside
DREAMFOLKS
Dreamfolks Services Ltd
115% Upside

Revenue
Forecast

17% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
17% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 7 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 12%.

Gross Profit
Forecast

25% / Year
Past Growth
13% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
25% / Year
Past Growth
13% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 7 years, the compound annual growth rate for Gross Profit has been 25%. The projected CAGR for the next 3 years is 13%.

Operating Income
Forecast

33% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
33% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 7 years, the compound annual growth rate for Operating Income has been 33%. The projected CAGR for the next 3 years is 17%.

Pre-Tax Income
Forecast

33% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
33% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been 33%. The projected CAGR for the next 3 years is 18%.

Net Income
Forecast

132% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
132% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 7 years, the compound annual growth rate for Net Income has been 132%. The projected CAGR for the next 3 years is 18%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MCAP's stock price target?
Price Target
652.8 SEK

According to Wall Street analysts, the average 1-year price target for MCAP is 652.8 SEK with a low forecast of 626.2 SEK and a high forecast of 693 SEK.

What is the Revenue forecast for MedCap AB (publ)?
Projected CAGR
12%

Over the last 7 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 12%.

What is the Gross Profit forecast for MedCap AB (publ)?
Projected CAGR
13%

Over the last 7 years, the compound annual growth rate for Gross Profit has been 25%. The projected CAGR for the next 3 years is 13%.

What is the Operating Income forecast for MedCap AB (publ)?
Projected CAGR
17%

Over the last 7 years, the compound annual growth rate for Operating Income has been 33%. The projected CAGR for the next 3 years is 17%.

What is the Pre-Tax Income forecast for MedCap AB (publ)?
Projected CAGR
18%

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been 33%. The projected CAGR for the next 3 years is 18%.

What is the Net Income forecast for MedCap AB (publ)?
Projected CAGR
18%

Over the last 7 years, the compound annual growth rate for Net Income has been 132%. The projected CAGR for the next 3 years is 18%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett